Travere Therapeutics is positioned for upside as FILSPARI sales accelerate and the critical FSGS PDUFA decision approaches in April. Read more on TVTX stock here.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2025 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results